Part B: Supplementary Information Sheet (SIS) |
FR Recognition List Number
|
043
|
Date of Entry 06/27/2016
|
FR Recognition Number
|
7-264
|
Standard | |
CLSI MM21-1st Edition (Reaffirmed: January 2020) Genomic Copy Number Microarrays for Constitutional Genetic and Oncology Applications |
|
Scope/AbstractThis guideline provides recommendations for validation, verification, performance, and interpretation of nucleic acid microarrays used for cytogenetic applications to measure copy number imbalances and loss of heterozygosity. Both constitutional and oncology applications are addressed. |
|
Extent of Recognition
Partial recognition. The following part(s) of the standard is (are) not recognized: |
Sub-Section 2.3.4. |
|
Public Law, CFR Citation(s) and Procode(s)*
Regulation Number |
Device Name |
Device Class |
Product Code |
866.5920 |
System, Microarray-Based, Genome-Wide, Postnatal Chromosomal Abnormality Detection
|
Class 2
|
PFX
|
|
Relevant FDA Guidance and/or Supportive Publications*
Appropriate Use of Voluntary Consensus Standards in Premarket Submissions for Medical Devices - Guidance for Industry and Food and Drug Administration Staff, issued September 2018. |
|
FDA Technical Contact
|
Standards Development Organization
|
FDA Specialty Task Group (STG)
|
*These are provided as examples and others may be applicable. |